中国临床药理学与治疗学2016，Vol.21Issue(5)：520-525,6.
Evolocumab治疗高胆固醇血症患者安全性的Meta分析
Meta-analysis of the safety of Evolocumab/AGM145 on treatment to hypercholesterolemia patients
摘要
Abstract
AIM:Evolocumab,also called AGM145,a fully human monoclonal antibody of proprotein convertase subtilisin-like/kexin type 9 (PC-SK9),has been approved by the FDA as a new lipid-lowering drug.We discussed the safety of Evolocumab treatment to hypercholesterolemia patients versus control groups.METHODS:The articles that met the inclusion criteria were retrieved from PubMed,Medline,Cochrane,EMBASE,BIOSIS Preview,SciFinder Scholar database,the Chinese biomedical literature database,VIP database,Wanfang database and CKNI database by computer and all these articles were studied using Review Manager 5.3 for meta-analysis and analysis of bias.RESULTS:9 articles and totally 4435 patients were included in this study.Meta-analysis results showed that there was no significant increasing of Evolocumab adverse events compared with placebo (OR 1.08,95％ CI 0.88-1.33).The any adverse events of Evolocumab were less than ezetimibe (OR 0.84,95％ CI 0.68-1.03),the serious adverse events of Evolocumab were no significant increasing than ezetimibe (OR 1.4,95％ CI 0.61-3.17).CONCLUSION:As a new lipid-lowering drug,Evolocumab significantly reduced low-density lipoprotein (LDL) cholesterol levels and showed no significant increasing on side effects compared with control groups and its serious side effects were rare.关键词
Evolocumab/AGM145/降脂药/高胆固醇血症Key words
Evolocumab/AGM145/lipid lowering drug/hypercholesterolemia分类
医药卫生引用本文复制引用
郑少微,巩付华,展淑琴,孙宏,杜赟,李燕玲,吴海琴,张桂莲..Evolocumab治疗高胆固醇血症患者安全性的Meta分析[J].中国临床药理学与治疗学,2016,21(5):520-525,6.基金项目
国家自然科学基金项目(81070999) （81070999）
中央高校基本科研业务费专项资金资助(xjj2014153,2009-95) （xjj2014153,2009-95）
西安交通大学第二附属医院人才培养专项科研基金科技骨干项目(RC(GG)201109) （RC(GG）
陕西科技攻关项目(2016SF-020) （2016SF-020）
